Welcome to our dedicated page for Aravive news (Ticker: ARAV), a resource for investors and traders seeking the latest updates and insights on Aravive stock.
Aravive, Inc. (Nasdaq: ARAV) is a late clinical-stage oncology company committed to developing targeted therapeutics for the treatment of metastatic diseases. With its headquarters in Houston, Texas, the company is at the forefront of cancer research aiming to improve the quality of life and outcomes for patients battling severe forms of cancer.
The company's lead product candidate, batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein designed to inhibit AXL receptor signaling by binding to its ligand GAS6. This mechanism is intended to prevent tumor growth and metastasis, as well as to restore sensitivity to existing anti-cancer therapies. Batiraxcept has received Fast Track Designation from the U.S. FDA for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer, along with Orphan Drug Designation from the European Commission for platinum-resistant recurrent ovarian cancer.
Despite recent challenges, such as the Phase 3 AXLerate-OC trial not meeting its primary endpoint in platinum-resistant ovarian cancer, Aravive remains committed to analyzing the complete dataset and determining the next steps for their other indications in renal cell carcinoma and pancreatic cancer. The Phase 3 trial involved 366 patients and aimed to evaluate the efficacy and safety of batiraxcept in combination with paclitaxel.
Aravive collaborates with renowned research groups, including The GOG Foundation, Inc. in the U.S. and the European Network for Gynecological Oncological Trials (ENGOT) in Europe. Funded by a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016, the company continues to innovate in the field of oncology.
For more information on their ongoing research and development efforts, please visit their website at www.aravive.com.
Aravive Inc. (ARAV) announced a $6 million milestone payment received from 3D Medicines for the initiation of a Phase 3 clinical trial evaluating batiraxcept for platinum-resistant ovarian cancer in China. This marks the third milestone achieved since their partnership began in November 2020, with total payments received reaching $27 million. The trial will enroll 300-400 patients and aims to assess the drug's efficacy and safety, with primary and secondary endpoints focusing on progression-free and overall survival.
On September 26, 2022, Aravive, a late clinical-stage oncology company, announced participation in the Cantor Fitzgerald Oncology & HemOnc Conference. CEO Gail McIntyre and CFO Rudy Howard will attend the event on September 28, 2022, at the Lotte New York Palace Hotel. Dr. McIntyre will participate in a panel discussion on 'Companies with Key Catalysts Over the Next 12-18 Months' at 10:40 am ET.
Aravive's lead product, batiraxcept, targets metastatic disease and has received Fast Track and Orphan Drug Designations for use in platinum-resistant ovarian cancer.
Aravive, Inc. (Nasdaq: ARAV) announced participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, at the Lotte New York Palace Hotel. CEO Gail McIntyre and CFO Rudy Howard will represent the company. The presentation will be available for viewing on September 12, 2022, at 7:00 am ET, with a 90-day archived replay accessible on the company’s website. Aravive is focused on targeted therapeutics for metastatic disease, with its lead candidate, batiraxcept, in multiple clinical trials and having received Fast Track Designation from the FDA.
Aravive, Inc. (ARAV) reported its Q2 2022 financial results, highlighting advancements in clinical trials for batiraxcept in metastatic cancers, including ovarian and renal cell carcinoma. The company is on track to complete enrollment for a Phase 3 trial in ovarian cancer by year-end 2022, with topline data expected mid-2023 and a BLA filing by year-end 2023. Q2 revenues reached $1.6 million, up from $1.1 million, while operating expenses increased to $21 million, resulting in a net loss of $18.5 million. Cash reserves stand at $46.8 million, projected to fund operations into Q1 2023.
Aravive, Inc., a leading clinical-stage oncology company, announced the appointment of Dr. Robert B. Geller as its new Chief Medical Officer. With over 30 years of experience in drug development, Dr. Geller will be pivotal in advancing the company's targeted therapeutics for treating metastatic cancers, particularly ovarian, renal, and pancreatic cancers. As Aravive prepares to file its first BLA by the end of 2023 and accelerate its ongoing clinical trials, Dr. Geller's extensive background in clinical and medical affairs is expected to enhance the likelihood of success for the company's lead product, batiraxcept.
Aravive, Inc. (Nasdaq: ARAV) has appointed Rudy Howard as its new Chief Financial Officer, effective immediately, following the resignation of Vinay Shah for personal reasons. Howard brings extensive financial experience from previous roles at vTv Therapeutics and MDS Pharma Services. CEO Gail McIntyre expressed confidence in Howard's capabilities to support the company's growth during this critical period. Aravive is focused on developing targeted therapeutics for metastatic diseases, with its lead candidate, batiraxcept, currently in several clinical trials.
Aravive, Inc. (Nasdaq: ARAV) announced the oral discussion of their Phase 1b/2 study of batiraxcept (AVB-S6-500) at the 2022 ASCO annual meeting. The abstract highlights promising results in advanced or metastatic clear cell renal cell carcinoma (ccRCC), indicating a 46% confirmed response rate and 71% progression-free survival at 7 months. A biomarker developed may enable a first-in-class targeted therapy in renal cancer, with a path for accelerated approval. Safety data showed no dose-limiting toxicities, supporting further clinical development.
Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company, will present at the H.C. Wainwright Annual Global Investment Conference from May 23-26, 2022. CEO Gail McIntyre will speak on May 25, 2022, from 10:00 am to 10:30 am ET at the Fontainebleau Miami Beach Hotel. Aravive focuses on developing targeted therapeutics for metastatic disease, with its lead candidate, batiraxcept, granted Fast Track and Orphan Drug Designations in ovarian cancer. The company is conducting multiple trials for batiraxcept in different cancer types. For more details, visit www.aravive.com.
Aravive, Inc. (Nasdaq: ARAV) reported a net loss of $13.1 million or $0.62 per share for Q1 2022, compared to a net loss of $8.0 million or $0.44 per share in Q1 2021. Revenue increased to $1.1 million from $0.3 million, primarily from a collaboration with 3D Medicines. The company strengthened its balance sheet with $20 million from recent fundraisings. Key developments include dosing the first patient in a Phase 2 trial for clear cell renal cell carcinoma and ongoing updates on the Phase 3 trial for ovarian cancer, with top-line data expected in 2Q 2023.
Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company, will host a Key Opinion Leader Symposium on May 11, 2022, focusing on the GAS6-AXL signaling pathway and its lead drug candidate, batiraxcept. The event starts at 8:00 am ET and will be available via live and archived webcast. Key presentations include updates on batiraxcept's role in treating platinum-resistant ovarian cancer, clear cell renal cell carcinoma, and pancreatic adenocarcinoma. Batiraxcept has received Fast Track Designation from the FDA and Orphan Drug Designation from the EU.
FAQ
What is the market cap of Aravive (ARAV)?
What is Aravive, Inc.?
What is batiraxcept?
What designations has batiraxcept received?
What was the outcome of the AXLerate-OC Phase 3 trial?
Where is Aravive, Inc. based?
Who are Aravive's research partners?
What is Aravive’s mission?
How is Aravive funded?
How can I find more information about Aravive?
What kind of cancer indications is Aravive focusing on?
